TY  - GEN
AU  - Blagden,Sarah
AU  - Omlin,Aurelius
AU  - Olmin,Aurelius
AU  - Josephs,Debra
AU  - Stavraka,Chara
AU  - Zivi,Andrea
AU  - Pinato,David J
AU  - Anthoney,Alan
AU  - Decordova,Shaun
AU  - Swales,Karen
AU  - Riisnaes,Ruth
AU  - Pope,Lorna
AU  - Noguchi,Kohei
AU  - Shiokawa,Rie
AU  - Inatani,Michiyasu
AU  - Prince,Jenny
AU  - Jones,Keith
AU  - Twelves,Chris
AU  - Spicer,James
AU  - Banerji,Udai
TI  - First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer
SN  - 1557-3265
PY  - 2015///0728
KW  - Administration, Oral
KW  - Adult
KW  - Aged
KW  - Antineoplastic Agents
KW  - pharmacology
KW  - Class I Phosphatidylinositol 3-Kinases
KW  - antagonists & inhibitors
KW  - Dose-Response Relationship, Drug
KW  - Female
KW  - Humans
KW  - Male
KW  - Maximum Tolerated Dose
KW  - Middle Aged
KW  - Neoplasm Metastasis
KW  - Neoplasms
KW  - diagnosis
KW  - Positron-Emission Tomography
KW  - Pyrimidines
KW  - Sulfonamides
KW  - Tomography, X-Ray Computed
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1158/1078-0432.CCR-14-1315
ER  -